ATE292641T1 - Mucin-mannan-konjugate und ihre immunotherapeutische anwendung - Google Patents

Mucin-mannan-konjugate und ihre immunotherapeutische anwendung

Info

Publication number
ATE292641T1
ATE292641T1 AT94303817T AT94303817T ATE292641T1 AT E292641 T1 ATE292641 T1 AT E292641T1 AT 94303817 T AT94303817 T AT 94303817T AT 94303817 T AT94303817 T AT 94303817T AT E292641 T1 ATE292641 T1 AT E292641T1
Authority
AT
Austria
Prior art keywords
conjugates
mucin
immunotherapeutic use
mannan conjugates
mannan
Prior art date
Application number
AT94303817T
Other languages
English (en)
Inventor
Ian Farquhar Mckenzie
Vasso Apostolopoulos
Geoff Allan Pietersz
Original Assignee
Ilexus Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilexus Pty Ltd filed Critical Ilexus Pty Ltd
Application granted granted Critical
Publication of ATE292641T1 publication Critical patent/ATE292641T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT94303817T 1993-12-24 1994-05-26 Mucin-mannan-konjugate und ihre immunotherapeutische anwendung ATE292641T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPM3223A AUPM322393A0 (en) 1993-12-24 1993-12-24 Mucin carbohydrate compounds and their use in immunotherapy

Publications (1)

Publication Number Publication Date
ATE292641T1 true ATE292641T1 (de) 2005-04-15

Family

ID=3777847

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94303817T ATE292641T1 (de) 1993-12-24 1994-05-26 Mucin-mannan-konjugate und ihre immunotherapeutische anwendung

Country Status (8)

Country Link
US (2) US5989552A (de)
EP (1) EP0659768B1 (de)
JP (2) JP3884088B2 (de)
AT (1) ATE292641T1 (de)
AU (1) AUPM322393A0 (de)
CA (1) CA2135833C (de)
DE (1) DE69434324T2 (de)
WO (1) WO1995018145A1 (de)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
WO1997010845A1 (en) * 1995-09-18 1997-03-27 Board Of Trustees Of The University Of Illinois An immunostimulant and antineoplastic glycan obtained from mycobacterium vaccae
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US20080286228A1 (en) * 1995-10-20 2008-11-20 Tarantolo Stefano R Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
AU703120B2 (en) * 1995-10-20 1999-03-18 University Of Nebraska Board Of Regents Composition and methods for enhancing immune responses mediated by antigen-presenting cells
EP0849275A1 (de) * 1996-09-26 1998-06-24 Rijksuniversiteit te Leiden Mannosylierte Peptide
WO1998028003A1 (en) * 1996-12-20 1998-07-02 Merck & Co., Inc. Formulations of recombinant papillomavirus vaccines
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
DE19740357A1 (de) * 1997-09-13 1999-03-18 Martin Wilhelm Phosphoryliertes Zuckermolekül
DK1027063T3 (da) 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannosereceptorbærende cellelinje og antigensammensætning
KR100680014B1 (ko) * 1997-10-03 2007-02-09 갈레니카 파마슈티칼스 인크. 이민 형성 폴리사카라이드, 이의 제조 방법 및 이것의 아쥬반트 및 면역자극제로서의 용도
EP1574217A1 (de) * 1997-10-03 2005-09-14 Galenica Pharmaceuticals, Inc. Iminbildende Polysaccharide, deren Herstellung und Verwendung als Zusatzmittel und Immunstimulierende Mittel
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
AU2903999A (en) * 1998-03-12 1999-09-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chemokine-tumor antigen fusion proteins as cancer vaccines
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
KR20010093290A (ko) 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
EP1046651A1 (de) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Zusammensetzungen und Verfahren zur Modulierung des interaktion zwischen dendritischer und T-zellen
GB9930359D0 (en) * 1999-12-22 2000-02-09 Glaxo Group Ltd Novel polypeptides
JP2003533181A (ja) * 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
AU780395B2 (en) * 2000-02-01 2005-03-17 Austin Research Institute, The Mucin-1 derived antigens and their use in immunotherapy
US6956119B2 (en) * 2000-03-21 2005-10-18 Hans Loibner Polysaccharide-polypeptide conjugate
AU2001263653B2 (en) * 2000-06-06 2006-06-29 Igavax Pty Ltd Vaccine
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US7323174B1 (en) 2000-06-12 2008-01-29 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulation of immune response and methods based thereon
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AU2001291050A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Viral chemokine-tumur antigen fusion proteins
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US7659240B2 (en) * 2002-01-14 2010-02-09 Vertex Pharmaceuticals Incorporated Mucin immobilized chromatography
AU2003233008B2 (en) * 2002-04-22 2008-04-24 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
GB0212036D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
AU2003258710A1 (en) * 2002-09-05 2004-03-29 Universitat Zu Koln Immunogenic muc1 glycopeptides
GB0304634D0 (en) * 2003-02-28 2003-04-02 Glaxo Group Ltd Vaccines
PL1642905T3 (pl) 2004-10-02 2009-04-30 Immatics Biotechnologies Gmbh Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy
ATE527285T1 (de) * 2005-01-28 2011-10-15 Univ Ramot Anti-muc1-alpha-beta-antikörper
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
EP1917041A4 (de) 2005-08-24 2010-09-29 Cedars Sinai Medical Center Verwendung von fruktosebasierten therapien zur krebsbehandlung
EP1760089B1 (de) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
EP1806358B1 (de) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden
GB2430881B (en) 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
JP2009544760A (ja) * 2006-01-23 2009-12-17 レコファーマ アーベー 酵母におけるオリゴマンノースまたはヒト様グリカンを担持するタンパク質の産生およびその使用
US20090181041A1 (en) * 2006-01-23 2009-07-16 Jan Holgersson Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
ES2555544T3 (es) * 2006-03-07 2016-01-04 Vaxinnate Corporation Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas
US20080031872A1 (en) * 2006-08-02 2008-02-07 Karp Nelson M HIV immunogenic composition and method of administration
WO2008063982A2 (en) * 2006-11-13 2008-05-29 Procell Corp High mannose glycoprotein epitopes
GB0707096D0 (en) 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
DK2183361T3 (en) 2007-07-27 2015-07-27 Immatics Biotechnologies Gmbh Novel immunotherapy against brain tumors
BRPI0814140A2 (pt) 2007-07-27 2017-03-28 Immatics Biotechnologies Gmbh composição de peptídeos associados a tumor e vacina anticâncer relacionada
BRPI0813626A2 (pt) 2007-07-27 2014-12-23 Immatics Biotechnologies Gmbh Epitopos imunogênicos para a imunoterapia
US8501907B2 (en) 2007-08-10 2013-08-06 Janssen Biotech, Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
CA2696011A1 (en) * 2007-08-10 2009-02-19 Centocor Ortho Biotech Inc. Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such
RU2527894C2 (ru) 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
ES2554981T3 (es) 2008-03-27 2015-12-28 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales
DE602008000891D1 (de) 2008-04-30 2010-05-12 Immatics Biotechnologies Gmbh Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
EP2334826A4 (de) 2008-09-12 2012-01-25 Cancer Res Initiative Foundation Verfahren für den nachweis und die diagnose oraler und nasopharyngealer tumoren
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB0904942D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0904941D0 (en) 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
CA2764197C (en) 2009-06-03 2017-09-12 Algipharma As Alginate oligomers for use in overcoming multidrug resistance in bacteria
EP2330122A1 (de) 2009-12-02 2011-06-08 Asklepios Kliniken Hamburg Gmbh OFA/iLRP-abgeleitetes modifiziertes Peptid
US9023802B2 (en) 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201019331D0 (en) 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
JP6096111B2 (ja) 2010-05-10 2017-03-15 アセンド・バイオファーマシューティカルズ・リミテッド 免疫刺激組成物及びワクチン組成物
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
GB201015765D0 (en) 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
GB201021289D0 (en) 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
SG191154A1 (en) 2010-12-14 2013-07-31 Immatics Biotechnologies Gmbh Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
AU2012334825B2 (en) * 2011-11-09 2017-08-24 Ascend Biopharmaceuticals Ltd Immunomodulatory conjugates
TWI777194B (zh) 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（一）
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6164759B2 (ja) 2013-11-21 2017-07-19 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 Ｔ細胞受容体およびｂ細胞受容体レパトアの解析システムならびにその治療および診断への利用
EP2883550A1 (de) 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Neuartige promiskuitive, HPV16-abgeleitete T-Helferepitope zur Immuntherapie
WO2015119180A1 (ja) 2014-02-06 2015-08-13 医化学創薬株式会社 ムチン４（ｍｕｃ４）糖ペプチドに対する抗体及びその用途
GB201408255D0 (en) 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
GB201411037D0 (en) 2014-06-20 2014-08-06 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
PL3545965T3 (pl) 2014-12-23 2021-12-27 Immatics Biotechnologies Gmbh Nowe peptydy i kombinacja peptydów do stosowania w immunoterapii względem raka komórek wątroby (hcc) i innych rodzajów raka
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
FI3273986T3 (fi) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201505585D0 (en) 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en) 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3919507A3 (de) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
CR20170579A (es) 2015-07-06 2018-05-25 Immatics Biotechnologies Gmbh Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
GB201522667D0 (en) 2015-12-22 2016-02-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603987D0 (en) 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
KR102411975B1 (ko) 2016-04-06 2022-06-22 이매틱스 바이오테크놀로지스 게엠베하 Aml 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
TWI796314B (zh) 2017-01-27 2023-03-21 德商英麥提克生物技術股份有限公司 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EP3609530A1 (de) 2017-04-10 2020-02-19 Immatics Biotechnologies GmbH Peptide und kombination davon zur verwendung in der immuntherapie gegen krebs
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
WO2018189152A2 (en) 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CN119080881A (zh) 2017-07-07 2024-12-06 伊玛提克斯生物技术有限公司 用于肺癌(包括nsclc、sclc和其他癌症)免疫治疗的新型肽和肽组合物
WO2019007974A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202016131A (zh) 2018-05-16 2020-05-01 德商英麥提克生物技術股份有限公司 用於抗癌免疫治療的肽
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
US11945850B2 (en) 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
TW202024121A (zh) 2018-09-18 2020-07-01 德商英麥提克生物技術股份有限公司 A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
US20220332764A1 (en) 2019-08-29 2022-10-20 Eberhard Karls Universität Tübingen T cell epitopes of hcmv and uses of thereof
EP3892297A1 (de) 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
EP3907284A1 (de) 2020-05-06 2021-11-10 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen hämatologische neoplasmen und andere krebsarten
EP3950705A1 (de) 2020-08-07 2022-02-09 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen eine infektion durch sars-cov-2 (covid-19)
TW202229312A (zh) 2020-09-29 2022-08-01 德商英麥提克生物技術股份有限公司 由非ｈｌａ－ａ*０２顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物
DE102020125457A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de) 2020-09-29 2022-03-31 Immatics Biotechnologies Gmbh Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh) 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
EP4337694A1 (de) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3- und gal3-hemmer, xbp1, cs1 und cd138-peptide und verfahren zur verwendung davon
CN117999350A (zh) 2021-06-25 2024-05-07 组库创世纪株式会社 一种t细胞表位序列的鉴定方法及其应用
WO2023283134A1 (en) 2021-07-05 2023-01-12 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
EP4198052A1 (de) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptide und antigenbindende proteine zur verwendung in der immuntherapie gegen fibrolamellares hepatozelluläres karzinom (fl-hcc) und andere krebsarten
EP4311834A1 (de) 2022-07-29 2024-01-31 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptide und kombinationen von peptiden zur verwendung in der immuntherapie gegen oropharyngeale plattenepithelkarzinome und andere krebsarten
EP4368189A1 (de) 2022-11-09 2024-05-15 Eberhard Karls Universität Tübingen, Medizinische Fakultät Peptide und kombinationen aus peptiden zur verwendung in der immuntherapie gegen akute myeloische leukämie (aml) und andere hämatologische neoplasmen
CN120603603A (zh) 2023-01-12 2025-09-05 瑞泽恩制药公司 用于靶向递送TGFβ的组合物和方法
WO2025040598A2 (en) 2023-08-18 2025-02-27 Immatics Biotechnologies Gmbh Peptides displayed by mhc for use in immunotherapy against different types of cancer
AU2024344227A1 (en) 2023-09-19 2026-04-30 Regeneron Pharmaceuticals, Inc. Viral peptides and uses thereof
WO2025136809A2 (en) 2023-12-19 2025-06-26 Regeneron Pharmaceuticals, Inc. Foxp3 peptides and uses thereof
WO2025178991A1 (en) 2024-02-21 2025-08-28 Regeneron Pharmaceuticals, Inc. Splicing factor gene mutation-associated neoantigenic peptides and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2279422A2 (fr) * 1974-07-22 1976-02-20 Inst Nat Sante Rech Med Forme pharmaceutique a base d'interferon
US4720386A (en) * 1976-11-24 1988-01-19 Mccollester Duncan L Vaccine and method for immunotherapy of neoplastic disease
US4415552A (en) * 1979-02-06 1983-11-15 The Governors Of The University Of Alberta Composition for establishing immunological tolerance
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
JPS61112023A (ja) * 1984-11-05 1986-05-30 Tanabe Seiyaku Co Ltd がん細胞傷害活性物質の新規製法
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
JP2594123B2 (ja) * 1987-09-12 1997-03-26 株式会社林原生物化学研究所 減感作剤
EP0326111A3 (de) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptid-Derivate, immunogenisch gemacht bei Verabreichung zusammen mit Alaun als Zusatzmittel
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
EP0357767B1 (de) * 1988-03-11 1995-05-24 The Biomembrane Institute Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden-trägerkonjugaten
JPH01233219A (ja) * 1988-03-12 1989-09-19 Nippon Oil & Fats Co Ltd 制癌剤組成物
ES2051909T3 (es) * 1988-04-19 1994-07-01 American Cyanamid Co Vacuna del conjugado de polisacarido-proteina de membrana externa contra la haemophilus influenzae tipo b.
AU620149B2 (en) * 1988-08-18 1992-02-13 Vaxine Pty Ltd Gamma inulin compositions
EP0442926A1 (de) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptide
DK0563278T3 (da) * 1990-12-20 2000-08-21 Dana Farber Cancer Inst Inc Regulering af geneekspression med ioniserende stråling
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1993006858A1 (en) * 1991-10-09 1993-04-15 Dana Farber Cancer Institute, Inc. Lung cancer-associated protein
IL104382A0 (en) * 1992-01-17 1993-05-13 Solvay Animal Health Inc Vaccine containing acemannan as an adjuvant
JP3043888B2 (ja) * 1992-02-20 2000-05-22 森永乳業株式会社 グルコマンナン部分加水分解物を有効成分とする大腸ガン予防剤
AU3746293A (en) * 1992-03-06 1993-10-05 Biocine S.P.A. Conjugates formed from heat shock proteins and oligo- or polysaccharides
IT1262896B (it) * 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
AU5675794A (en) * 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression

Also Published As

Publication number Publication date
EP0659768A2 (de) 1995-06-28
DE69434324D1 (de) 2005-05-12
EP0659768A3 (de) 1996-12-18
EP0659768B1 (de) 2005-04-06
US5989552A (en) 1999-11-23
DE69434324T2 (de) 2006-03-09
JP4701146B2 (ja) 2011-06-15
CA2135833C (en) 2008-09-09
AUPM322393A0 (en) 1994-01-27
JP3884088B2 (ja) 2007-02-21
CA2135833A1 (en) 1995-06-25
US6177256B1 (en) 2001-01-23
WO1995018145A1 (en) 1995-07-06
JP2007197419A (ja) 2007-08-09
JPH07206707A (ja) 1995-08-08

Similar Documents

Publication Publication Date Title
DE69434324D1 (de) Mucin-Mannan-Konjugate und ihre immunotherapeutische Anwendung
ATE475668T1 (de) Immunisierung durch impfung von dns transkriptionseinheit
ATE229978T1 (de) Helicobacter proteine und impstoffe
CA2245497A1 (en) Peptide immunogens for vaccination against and treatment of allergy
DE69030172D1 (de) Impfstoffe gegen Krebs und Infektionskrankheiten
FI953608A7 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalv ossa järjestelmällisellä rokottamisella
AU3272495A (en) Novel vaccine adjuvant and vaccine
EP1712628A3 (de) Verbindungen und Verfahren zur Immuntherapie und Diagnose von Tuberkulose
AU1316495A (en) Vaccines
BR9610679A (pt) Antígenos de leishmania para uso na terapia e disgnose da leishmaniose
NL300400I1 (en) Method and manufacture of an acellular vaccine comprising Bordetella pertussis antigens
WO2000025815A8 (en) Novel immunoadjuvants
ATE220687T1 (de) Die erzeugung einer immunantwort gegen erwünschte determinanten
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
FI955150L (fi) OspC-antigeenirokotteiden immunogeenisia formulaatioita lyymisairauden ehkäisyyn ja hoitoon ja rekombinanttimenetelmiä antigeenien valmistamiseksi
EP1891968A3 (de) Rotavirusimpfstoff-Formulierungen
DE69018729D1 (de) Bildgebendes Gerät und Methode.
GR3019356T3 (en) Recombinant mycoplasma hyopneumoniae antigen and uses therefor
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
DE69729425D1 (de) Nicht-virulentes Mycoplasma synoviae und Impfstoffe desselben
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
MA23139A1 (fr) Composition therapeutique nouvelle ayant un effet immunostimulant .
ATA211388A (de) Gegen pseudomonas aeruginosa-infektionen wirksame praeparationen sowie immunglobuling-h|ltige, gegen bakterium pseudomonas aeruginosa wirksame praeparationen
FR2708855B1 (fr) Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes.
SE9600646D0 (sv) Vaccin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties